within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX12_Viltolarsen;

model Viltolarsen
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 3.3055555555555558e-06,
    adminDuration = 600,
    adminMass = 80 / 1000000,
    adminCount = 1,
    Vd = 0.0002,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Viltolarsen</td></tr><tr><td>ATC code:</td><td>M09AX12</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>80</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.17</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Viltolarsen is an antisense oligonucleotide drug designed to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation amenable to exon 53 skipping. It is administered intravenously and was approved by the FDA in August 2020 for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in ambulatory pediatric male patients (ages 4 to <10 years) with Duchenne muscular dystrophy after single and multiple intravenous infusions.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M09AX12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Viltolarsen;
